Skip to main content
. 2020 Nov 28;223(4):589–599. doi: 10.1093/infdis/jiaa737

Figure 5.

Figure 5.

SARS-CoV-2 neutralizing antibodies in HCW. A, MN titers of HCW with positive or intermediate SARS-CoV-2 RBD screening results (n = 76). C, Live VN titers of HCW positive with MN antibodies (n = 11). Each circle represents 1 HCW (gray baseline and purple follow-up). Horizontal lines represent geometric mean with 95% confidence interval. HCW were divided into seroconverters (blue circle) who had ≥4-fold increase in (B) MN and (D) VN titers and nonseroconverters (gray circle) who had <4-fold increase in titers. Their respective fold changes in MN and VN titers are plotted on the right y-axis with horizontal lines representing the mean with standard error of the mean. Dotted lines represent positive neutralizing antibody titers of 20. Individuals with undetectable antibodies were assigned a titer of 10 for plotting and calculation purposes. MN and VN titers were log-transformed and compared between time points in mixed-effects models with adjustment for subject variation, age, sex, and other relevant demographic factors. **P < .01. Abbreviations: HCW, health care workers; MN, microneutralization; RBD, receptor-binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VN, virus neutralization.